At the interface between these circulating factors and insulin/glucagon secretion are GPCRs, which in islets mediate the effects of many of the circulating factors, such as glucagon-like peptide-1 ...

GPCRs are the targets for around one third of all approved drugs 1. Yet such medicines act on only a handful of the 800+ known GPCRs. A wave of biomedical progress in the early 21 st century ...

The poster presentations will highlight Domain’s progress in leveraging GPCR-targeting therapies to modulate the tumor microenvironment and enhance anti-cancer immune responses. DT-7012 – A ...